AstraZeneca shares drop by 6% after halting COVID-19 vaccine trials
Category: #headlines  By Nikita Chaurasia  Date: 2020-09-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca shares drop by 6% after halting COVID-19 vaccine trials

AstraZeneca plc, a British-Swedish pharmaceutical & biopharmaceutical leader, has recently made it to the headlines for witnessing a 6% plunge in shares after voluntarily halting its late-stage trial for a potential COVID-19 vaccine.

Sources close to the matter cited that the company had put the trial on hold as mean of caution after a study participant in the United Kingdom was experiencing adverse reactions of the potential vaccine.

For the uninitiated, AstraZeneca had developed a vaccine called AZD1222 which was engineered to use a modified adenovirus that carries certain genetic materials of the coronavirus.

The vaccine uses the technology that was employed for developing an experimental Ebola vaccine that was catered to people in the Democratic Republic of Congo in the year 2019, sources claimed.

It is to be noted that the U.S. government struck a deal with AstraZeneca and funded over USD 1.2 billion for the development of a COVID-19 vaccine as well as to secure at least 300 doses for the U.S. population.

Researchers involved in the trials claimed that the AZD1222 vaccine showed no adverse effects apart from headache, fatigues, muscle pain, and fever. The nature of the case leading to the suspension of the trials is not known, however, the volunteer is expected to recover soon.

Evidently, AstraZeneca had commenced the trial round towards the end of last month and is one of three companies to initiate late-stage testing for a potential vaccine. The other two companies are Massachusetts-based biotech company Moderna and Pfizer Inc., a renowned pharmaceutical corporation.

In other news, the Russian Health Ministry has reportedly initiated the distribution of the first batch of the COVID-19 vaccine Sputnik V, which is developed by Gamaleya National Research Center of Epidemiology & Microbiology.

Source credits: https://www.cnbc.com/2020/09/08/astrazeneca-shares-fall-after-coronavirus-vaccine-study-is-put-on-hold.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...

FAA grants approval for mass air shipment of Pfizer’s COVID-19 vaccine
FAA grants approval for mass air shipment of Pfizer’s COVID-19 vaccine
By Nikita Chaurasia

Chicago-headquartered airline company United Airlines Inc. has reportedly started operating charter flights for the distribution of Pfizer Inc.’s COVID-19 vaccine after receiving approval from the Federal Aviation Authority (FAA). For the reco...